Who is sponsoring NCT03913494?

NCT03913494 is sponsored by University of California, San Diego.

What drugs are being tested in NCT03913494?

Interventions in NCT03913494: Transoral Neurostimulation Device (Snoozeal).

What condition does NCT03913494 study?

NCT03913494 studies Sleep Apnea, Obstructive, Sleep Apnea, Sleep, Snoring.

Is NCT03913494 still recruiting?

NCT03913494 is currently completed. Last updated 6 April 2021.

Last reviewed 2021-04-06 · How we verify

NCT03913494: SnooZeal-snore

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Transoral Daytime Neuromuscular Electrical Stimulation in Patients With Simple Snoring

Completed NA Last updated 6 April 2021

What this trial tests

NA trial testing Transoral Neurostimulation Device (Snoozeal) in Sleep Apnea, Obstructive in 48 participants. Completed in 20 February 2020.

Timeline

30 July 2019

Primary endpoint
20 February 2020

20 February 2020

Quick facts

Lead sponsor	University of California, San Diego
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	48
Start date	30 July 2019
Primary completion	20 February 2020
Estimated completion	20 February 2020
Sites	2 locations across United States

Drugs / interventions tested

Transoral Neurostimulation Device (Snoozeal)

Conditions studied

Sleep Apnea, Obstructive — all drugs for Sleep Apnea, Obstructive →
Sleep Apnea — all drugs for Sleep Apnea →
Sleep — all drugs for Sleep →
Snoring — all drugs for Snoring →

Sponsor

University of California, San Diego

Who can join

Adults 18 to 65, any sex, with Sleep Apnea, Obstructive or Sleep Apnea. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Sleep Disordered Breathing (SDB) is a spectrum of conditions spanning from Simple Snoring to Severe Sleep apnea. SDB has multiple underlying mechanisms. Some portion of patients have issues with upper airway dilator muscle control; and such patients may be amenable to upper airway muscle training exercises using neuromuscular stimulation techniques. The investigators and others have published on the topic of neuromyopathy in the upper airway, defining a subgroup of OSA patients who may be amenable to training exercises. Based on this background, the investigators seek to test the hypothesis that upper airway tongue muscle training using transoral surface neuromuscular electrical stimulation may have benefits to patients with Simple Snoring.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Transoral awake state neuromuscular electrical stimulation therapy for mild obstructive sleep apnea.
Nokes B, Baptista PM, de Apodaca PMR, Carrasco-Llatas M, et al · · 2023 · cited 9× · PMID 35624401 · DOI 10.1007/s11325-022-02644-9
The impact of daytime transoral neuromuscular stimulation on upper airway physiology - A mechanistic clinical investigation.
Nokes B, Schmickl CN, Brena R, Bosompra NN, et al · · 2022 · cited 5× · PMID 35748091 · DOI 10.14814/phy2.15360

Verify or expand the search:

Other recruiting trials for Sleep Apnea, Obstructive

Currently open trials in the same condition.

NCT06828835 — The REPOSE (Reach for Equity in Pediatric Sleep Evaluation) Navigation Intervention · NA · recruiting
NCT06915831 — Type 1 Diabetes and Obstructive Sleep Apnea · NA · recruiting
NCT07176767 — The IPAD Cohort Study: Insomnia and Positive Airway Pressure Adherence in Children and Adolescents · recruiting
NCT06573372 — Evaluating the Diagnostic Efficacy of Smartwatch and Smartphone for Sleep Apnea · recruiting
NCT06848647 — Treatment of Sleep Apnea to Improve Metabolic Health · recruiting

Other University of California, San Diego trials

Trials by the same sponsor.

NCT07342543 — Guided Physical Activity Counseling for Hypertension in Primary Care · NA · not yet recruiting
NCT06505317 — Artificial Intelligence for Early Detection of Peripheral Artery Disease · NA · not yet recruiting
NCT07211802 — CKM For Safe Use of SGLT2i in Type 1 Diabetes · Phase 3 · not yet recruiting
NCT07524751 — Culturally Adapted Pain Management for Indigenous Peoples · NA · not yet recruiting
NCT07518784 — Accurate Point of Care Liver Disease Diagnostics (Phase 2) · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03913494 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, San Diego
Last refreshed: 6 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03913494.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing